Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ADVATE 2 mL (Reconstituted in 2 mL SWFI) POST-AUTHORIZATION SAFETY SURVEILLANCE STUDY

NCT02093741 is registered in ClinicalTrials.gov with Baxalta now part of Shire as lead sponsor.

NCT NCT02093741
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02093741 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ADVATE 2 mL (Reconstituted in 2 mL SWFI) POST-AUTHORIZATION SAFETY SURVEILLANCE STUDY
Lead sponsor
Baxalta now part of Shire
Phase
Observational
Overall status
Completed
Start date
September 20, 2013
Completion date
January 20, 2016
Enrollment
65 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

congenital factor viii (fviii) deficiency, hemophilia a